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Transcranial direct current
stimulation as a treatment for
auditory hallucinations
Sanne Koops , Hilde van den Brink and Iris E. C. Sommer*
Psychiatry Department, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
Auditory hallucinations (AH) are a symptom of several psychiatric disorders, such as
schizophrenia. In a significant minority of patients, AH are resistant to antipsychotic
medication. Alternative treatment options for this medication resistant group are scarce
and most of them focus on coping with the hallucinations. Finding an alternative
treatment that can diminish AH is of great importance. Transcranial direct current
stimulation (tDCS) is a safe and non-invasive technique that is able to directly influence
cortical excitability through the application of very low electric currents. A 1–2 mA direct
current is applied between two surface electrodes, one serving as the anode and the
other as the cathode. Cortical excitability is increased in the vicinity of the anode and
reduced near the cathode. The technique, which has only a few transient side effects
and is cheap and portable, is increasingly explored as a treatment for neurological
and psychiatric symptoms. It has shown efficacy on symptoms of depression, bipolar
disorder, schizophrenia, Alzheimer’s disease, Parkinson’s disease, epilepsy, and stroke.
However, the application of tDCS as a treatment for AH is relatively new. This article
provides an overview of the current knowledge in this field and guidelines for future
research.
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Hallucinations in Psychotic Disorders
Auditory hallucinations (AH) are a frequent symptom of schizophrenia which occurs in
about 60–80% of patients (Andreasen and Flaum, 1991). The content of these hallucinations
is mostly negative, often conveying anger (McCarthy-Jones et al., 2014), or terms of abuse
(Nayani and David, 1996) and increasing the risk for suicidal behavior (Harkavy-Friedman et al.,
2003). Furthermore, AH also occur in other diagnostic groups such as borderline personality dis-
order, anxiety disorders, aﬀective disorders, posttraumatic stress disorder, autism, and signiﬁcant
hearing loss (Sommer et al., 2012b).
In approximately 70–75% of these cases, antipsychotic medication and/or cognitive behavioral
therapy suﬃciently suppress AH. However, the remaining 25–30% continues to suﬀer from AH
despite optimal therapy (Shergill et al., 1998). Alternative treatment options are scarce for this
group of patients, and often focus on coping with the hallucinations and accepting their pres-
ence instead of reducing them (Bentall et al., 1994). Due to the distressing impact AH have on
the patients’ quality of life, their ability to concentrate and their social and professional function-
ing, ﬁnding an eﬀective treatment option to reduce AH in this treatment-resistant group would be
of great value.
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Transcranial Direct Current Stimulation
Transcranial direct current stimulation (tDCS) is a non-invasive
focal neurostimulation technique that involves the application
of a low intensity electric current between two surface elec-
trodes, an anode and a cathode (Nitsche et al., 2008). A 1–2 mA
direct current is applied between two electrodes, often with a
size of 35 cm2 (5 cm × 7 cm), which are placed on the scalp.
The current ﬂows between the anode and the cathode, some of
it being diverted through the scalp and another part moving
through the brain where brain activity is modulated. Although
the exact mechanisms of action of tDCS have yet to be com-
pletely elucidated, there are two mechanisms by which tDCS
modulates brain activity that are currently widely accepted in
the ﬁeld (Brunoni et al., 2012). The ﬁrst proposes that the cur-
rent that passes through the brain modulates levels of corti-
cal excitability in a polarity dependent manner (Miranda et al.,
2006). Cortical excitability is thought to be increased in the
vicinity of the anode and reduced near the cathode. The anodal
and cathodal eﬀects of tDCS on cortical excitability are thought
to be explained by shifts in the resting membrane potential
(depolarization and hyperpolarization). The second proposes
that prolonged eﬀects of tDCS can be explained by modi-
ﬁcations of N-methyl-D-aspartate (NMDA) receptor eﬃcacy,
changes in gamma-aminobutyric acid-ergic activity and modu-
lation of interneurons, resulting in prolonged synaptic eﬃcacy
changes (Nitsche et al., 2008; Stagg and Nitsche, 2011). However,
most of what we know about the eﬀects of tDCS on a neu-
ral level is derived from studies of the primary motor cortex
(Nitsche et al., 2008). Questions can be raised concerning the
generalizability of these underlying mechanisms to other cortical
areas (Horvath et al., 2015).
In the 1960s, tDCS was studied extensively, but never gained
much popularity in clinical practice (Priori, 2003). Currently,
this seems to be changing as tDCS is increasingly explored
for the treatment of both neurologic and psychiatric symptoms
(Boggio et al., 2008). It has shown eﬃcacy on the clinical symp-
toms of depression, on both depressive and manic symptoms of
bipolar disorder, cognitive functioning in schizophrenia, episodic
memory in Alzheimer’s disease, motor symptoms and work-
ing memory in Parkinson’s disease, on the amount of insults
in epilepsy, on rehabilitation of motor function, and language
disorder after stroke and on tinnitus (Floel, 2014; Kuo et al.,
2014). tDCS is a safe treatment with few, if any, side eﬀects
(Nitsche et al., 2008). Some mild side eﬀects of a transient nature
that have been mentioned in association with tDCS are a slight
headache, an itching or tingling sensation at the location of the
electrodes and redness of the skin at the location of the elec-
trodes. However, such side eﬀects are also reported after placebo
(sham) treatment (Brunoni et al., 2014). Other advantages of this
technique are that tDCS equipment is relatively cheap, the treat-
ment can be given after a short training course, and it is easily
portable.
Compared to transcranial magnetic stimulation (TMS),
another form of focal stimulation that has often been used as an
alternative treatment option for AH (Slotema et al., 2014), tDCS
has some explicit beneﬁts when using it for research. It is easier to
apply an identical placebo treatment, as less physical sensations
occur compared to TMS. The itching or tingling sensation that
is sometimes mentioned by participants is often only present at
the start of treatment and disappears quickly. To mimic this in a
placebo treatment, it helps to start with a short period of active
stimulation (30–40 s) after which stimulation slowly regresses.
During the rest of the treatment period, no active stimulation
takes place. This short active stimulation period does not have
modulating eﬀects on the brain, but it properly mimics the phys-
ical sensations of active treatment. Furthermore, it is possible to
preprogram tDCS equipment to apply placebo treatment, which
makes it easier to perform double blind sham-controlled trials
(Nitsche et al., 2008).
Transcranial Direct Current Stimulation
in AH
The use of tDCS as a treatment option for medication resistant
AH is relatively new and has till now only been tested in patients
with AH in the context of psychotic disorders. Homan et al.
(2011) were the ﬁrst to explore this in a case study. For 10 con-
secutive days, the patient received daily treatment of 15min tDCS
at an intensity of 1 mA. The cathode was placed on the left tem-
poroparietal cortex (TPC), a location that has been linked to the
experience of AH (Silbersweig et al., 1995; Shergill et al., 2000).
The anode was placed on the right supraorbital area. Using this
method, they were able to ameliorate medication resistant AH.
Moreover, this eﬀect was still present 6 weeks after treatment.
A more recent case study reported a reduction of 90% in AH
severity after 2 months of daily 20 min tDCS at an intensity of
1 mA (Andrade, 2013). After this, treatment was increased to
twice daily and an intensity of 3 mA, which led to increased
improvement in AH severity. This improvement was still present
after 3 years of daily maintenance treatment, but when treat-
ment frequency was reduced to once per 2 days the ameliorating
eﬀects disappeared. In this study, the cathode was also placed
on the left TPC, but the anode was placed on the left dorsolat-
eral prefrontal cortex (DLPFC). This is an area that is often used
in studies investigating the eﬀects of tDCS on cognitive func-
tioning (Hoy et al., 2014). These two tDCS locations have been
used in several other case studies reporting positive eﬀects of
tDCS on AH severity after multiple sessions of 20 min tDCS at
an intensity of 2 mA (Rakesh et al., 2013; Shiozawa et al., 2013;
Shivakumar et al., 2013; Nawani et al., 2014). However, all these
studies were open-label without a control condition, meaning
that non-speciﬁc eﬀects (i.e., placebo-eﬀects) may have been of
large inﬂuence. Brunelin et al. (2012) were the ﬁrst to publish a
tDCS study in AH in which a control group was included. In this
study, 15 patients received a 20 min tDCS treatment twice daily
at an intensity of 2 mA, for 5 consecutive days and an equal num-
ber of patients received sham. In this study, the cathode was also
placed on the left TPC and the anode on the left DLPFC. They
found a robust decrease in AH severity of 30% compared to a
placebo group of equal size. Furthermore, a signiﬁcant decrease
was found in other symptoms as measured by the Positive and
Negative Syndrome Scale (PANSS), such as negative symptoms.
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These positive eﬀects were still present after 3 months. A more
recent study by the same group, using a partially overlapping
sample of 28 patients and identical methods, reported a decrease
of 46% in AH frequency in medication resistant patients after
active treatment, whereas no such eﬀect occurred in the placebo
group (Mondino et al., 2014). A recent open label study includ-
ing 21 patients with schizophrenia and the same stimulation
parameters and locations as Brunelin et al. (2012) found a similar
improvement of 32% in AH severity. However, this study did not
include a placebo condition (Bose et al., 2014). Up till now, one
pilot study has been published that reports no beneﬁcial eﬀect of
tDCS treatment on AH (Fitzgerald et al., 2014). This study tested
the eﬀects of both unilateral (N = 13) and bilateral (N = 11)
tDCS on AH compared to placebo. In total, patients underwent
15 treatments in 3 weeks time. The AH did not respond to either
treatment method. However, it is important to note that this
study had a very small sample size and rated AH severity based on
the PANSS only. This scale does not measure AH in much detail
and the diﬀerent severity scores of the hallucination item are
found to be hard to diﬀerentiate (Santor et al., 2007). Other stud-
ies mostly use the Auditory Hallucination Rating Scale (AHRS) to
measure AH severity. See Table 1 for a summary of all included
studies.
It is still unclear in what way tDCS might inﬂuence AH. As
all studies that report positive results up till now have used the
left TPC as the location for the cathode, it appears that the
inhibiting action of tDCS on that speciﬁc location is important
for the beneﬁcial eﬀects. It is unclear if excitation on the left
DLPFC also inﬂuences AH severity. Brunelin et al. (2012) asso-
ciated excitation on this location with a decrease of negative
symptoms. However, Andrade (2013) found that using a more
neutral position for the anode, namely the left mastoid, caused
the beneﬁcial eﬀects on AH to vanish. This implicates that the
excitatory eﬀect of the anode on the DLPFC is important to
induce a beneﬁcial eﬀect on AH. Possibly this can be explained
by a positive eﬀect from anodal stimulation of the left DLPFC on
working memory. This hypotheses is mainly derived from liter-
ature on tinnitus, for which tDCS has also been reported to be
eﬀective. Like schizophrenia, tinnitus has been associated with
reduced executive control (Heeren et al., 2014). Besides, tinni-
tus has been found to be alleviated by tDCS over the DLPFC
(Frank et al., 2012). These authors hypothesized that improved
executive control, as induced by tDCS over the DLPFC, acts as
a mediator for the impact from tDCS on tinnitus (Heeren et al.,
2014). It may be that a similar therapeutic mechanism is involved
in the therapeutic eﬀect of tDCS for AH. Reduced inhibition of
irrelevant verbal information may be an important underlying
mechanism of AH, speculatively AH could result from misat-
tribution of self-generated information to an external source
(Daalman et al., 2011). Application of anodal tDCS over de left
DLPFC has been found to enhance working memory, which
plays an important role in the executive control of informa-
tion (Brunoni and Vanderhasselt, 2014). It could therefore be
speculated that anodal tDCS over the left DLPFC induces the
ameliorating eﬀects on AH by improving the inhibition of irrele-
vant verbal information. Whether this excitation must take place
at the left DLPFC is, however, yet unclear, as the ﬁrst case study
in this ﬁeld used the right supraorbital area for the anode and still
showed a positive result (Homan et al., 2011). Moreover, tDCS
does not only produce focal eﬀects but also indirect eﬀects on sur-
rounding brain areas and their connections (Keeser et al., 2011).
The more distal eﬀects of tDCS could also be of inﬂuence on
the ameliorating eﬀects on AH. Imaging studies combined with
tDCS in AH could provide more insight in the exact neurological
underpinnings of the eﬀects of this treatment.
Taken together, the results of tDCS as an alternative treat-
ment option for AH are preliminary and so far mostly positive.
However, a note of caution may be in place here. When new
treatment strategies are introduced, the initial reports tend to fea-
ture relatively small sample sizes and favorable results, whereas
small studies with negative ﬁndings do not tend to be published
(Emerson et al., 2010; Sommer et al., 2012a). With an increase of
studies with larger sample sizes over time, negative ﬁndings tend
to become published as well. Such trends have led eﬀect sizes to
decrease per year of publication (Munafo and Flint, 2010). This
eﬀect has also been visible in the application of TMS for AH
(Slotema et al., 2012). As tDCS in the treatment of AH is a young
treatment method, future studies may well show less favorable
results. In the University Medical Center Utrecht, we have started
a large randomized double blind trial to investigate the eﬀects of
tDCS on AH. We plan to include 62 patients and expect to be
able to report results in autumn 2015. It is important to await
such studies with large sample sizes before conclusions are drawn
about the eﬃcacy of tDCS. This also means that there is a large
responsibility for scientiﬁc periodic journals to also publish neg-
ative ﬁndings of such treatments, to help reduce publication bias
for positive results.
Moreover, it is of importance that placebo treatments in dou-
ble blind trials are hard to distinguish from active tDCS treat-
ment. At this point, all placebo-controlled trials in this ﬁeld
have used tDCS at an intensity of 2 mA (Brunelin et al., 2012;
Fitzgerald et al., 2014; Mondino et al., 2014). For 1 mA tDCS, it
has been reported that placebo treatment is highly identical to
active treatment. Both participants and investigators were not
able to distinguish between the two (Gandiga et al., 2006). This
provides conﬁdence that both participants and investigators will
remain well blinded throughout the duration of a double blind
trial. However, it is yet unsure if the same applies for tDCS stim-
ulation at 2 mA, as the physical sensations at this intensity are
more pronounced and redness of the skin may occur. Although
the literature is still unclear if participants themselves are able to
diﬀerentiate between 2 mA active stimulation and placebo treat-
ment, it has been found that redness of the skin is a possible clue
for researchers to diﬀerentiate between the two (O’Connell et al.,
2012; Palm et al., 2013). However, it is important that these results
stem from crossover studies, in which subtle diﬀerences between
treatments and the eﬀects on each individual participant attract
more attention. Brunoni et al. (2014) investigated tDCS blinding
of 2 mA stimulation in a large sample of patients with a depres-
sion disorder, using a parallel design. Each patient received either
active or placebo treatment. They found that patients were able
to identify 2 mA active treatment above chance level, but this
appeared to be related to the occurrence of clinical response.
Patients who did not show clinical response to treatment were
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not able to identify active treatment. However, this study did not
mention results about the accuracy of blinding in tDCS oper-
ators, which were diﬀerent investigators than the assessors of
the clinical eﬀect of the treatment. Knowing if a parallel design
has advantages for the accuracy of blinding in tDCS operators
is important to assess the reliability of results from double blind
studies using placebo-controlled tDCS in parallel designs.
At this time, studies using tDCS in AH have highly similar
methods, using 15–20 min of treatment at 1–2 mA and mostly
placing the electrodes over the left TPC and left DLPFC. Future
research could further investigate if these are indeed the most
optimal parameters and locations for tDCS in AH. In TMS, the
left TPC is also the most used brain area for inhibitory stimula-
tion as a treatment for AH. Multiple attempts at other locations
for TMS did not lead to positive results compared to placebo
(Slotema et al., 2014). Considering that, the choice for the left
TPC as a location for the cathode in tDCS seems logical. However,
it may be worth the eﬀort to test the eﬃcacy of both cathodal and
anodal tDCS on other brain areas that have been associated with
AH.
Furthermore, the precision of the treatment in inﬂuencing
the targeted brain areas could possibly be optimized. In most
studies, relatively large electrodes are used with a surface size
of 35 cm2. However, it is also possible to use smaller electrodes
with a surface size of 25 cm2 or even so called ‘high deﬁnition’
tDCS in which electrodes are used with a diameter of 12 mm
or less (Minhas et al., 2010). Such a method may increase the
precision of treatment by decreasing the amount of electricity
that is lost due to distribution over the scalp. But using smaller
electrodes should be investigated thoroughly, as the neuromodu-
lating eﬀects of small electrodes can strongly diﬀer from those of
big electrodes (Nitsche et al., 2008). It is possible that the desired
eﬀects are eliminated instead of increased using small electrodes,
as they are designed for more focal eﬀects and will have less eﬀect
on surrounding brain areas and their connections. The use of
small electrodes also increases the need for more precision in
placing the electrodes on the scalp. Currently, electrode place-
ment is mostly done using the international 10–20 system for
EEG electrode placement (Jasper, 1958), but it is unclear whether
this oﬀers enough precision when using smaller electrodes. A
stereotactic neuronavigation technique based on an individual’s
structural MRI image may be a suitable option to oﬀer more reli-
ability that the focus of tDCS treatment is targeted at the right
brain area (Neggers et al., 2004; Fitzgerald et al., 2009; Sack et al.,
2009).
Conclusion
At this moment, tDCS appears to be a possible new treatment
option to help reduce treatment-resistant AH. However, as cur-
rently only three randomized controlled trials have been pub-
lished with relatively small sample sizes, two of which reporting
positive results and one with non-signiﬁcant results, insuﬃcient
data is available to determine if tDCS treatment is indeed eﬀec-
tive in AH. Future placebo-controlled trials in large samples
will have to assess if the mainly positive results up till now can
be replicated. Furthermore, diﬀerent methods and parameters
for stimulation, localization, and precision of tDCS should be
investigated in more detail to further optimize this treatment.
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